---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-023674"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:27:14.038638+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics stockholders elect three Class II directors and ratify auditor at 2022 annual meeting

## Summary
- Martin Babler elected with 27,034,110 votes for; 54,875 withheld; 1,215,046 broker non-votes.
- Julian Baker elected with 25,635,979 votes for; 1,453,006 withheld; 1,215,046 broker non-votes.
- Victor Sandor elected with 26,057,360 votes for; 1,031,625 withheld; 1,215,046 broker non-votes.
- Ernst & Young ratified as independent auditor for FY2022: 28,293,151 for, 5,385 against, 5,495 abstain.

## SEC filing metadata
- accession: 0001564590-22-023674
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000156459022023674/0001564590-22-023674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000156459022023674/prld-8k_20220617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-023674
- JSON: https://secwatch.observer/filing/0001564590-22-023674.json
- Plain text: https://secwatch.observer/filing/0001564590-22-023674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.